Methods of enhancing expression of somatostatin in pancreatic endocrine cells

• US 10,519,424 B2
• Filed: 08/31/2018
• Issued: 12/31/2019
• Est. Priority Date: 06/08/2012
• Status: Active Grant

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Rezania, Alireza
• Primary Examiner(s): Lankford, Blaine
• Application Number:
  US16/119,862
• Publication Number:
  US 20180371420A1
• Time in Patent Office: 487 Days
• Field of Search: None
• CPC Class Codes: C12N 2501/50 Cell markers; Cell surface determinants
• CPC Class Codes: C12N 2501/998 Proteins not provided for elsewhere
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention provides methods to promote differentiation of pancreatic endoderm cells to pancreatic endocrine rich clusters and to enhance insulin expression in hormone-expressing cells.

Claims

1. A method of enhancing expression of somatostatin in pancreatic endocrine cells, comprising culturing pancreatic endoderm cells in medium comprising Activin A or Activin C, thereby generating pancreatic endocrine cells having enhanced expression of somatostatin.

2. The method of claim 1, wherein expression of insulin, glucagon, and ghrelin is suppressed in the pancreatic endocrine cells.

3. The method of claim 1, wherein the pancreatic endocrine cells expresses more somatostatin compared to pancreatic endocrine cells generated from pancreatic endoderm cells non-treated with Activin A or Activin C.

4. The method of claim 1, wherein expression of insulin is suppressed in the pancreatic endocrine cells generated from the pancreatic endoderm cells cultured with Activin A or Activin C as compared to expression of insulin in pancreatic endocrine cells generated from pancreatic endoderm cells non-treated with Activin A or Activin C.

5. The method of claim 1, wherein expression of glucagon is suppressed in the pancreatic endocrine cells generated from the pancreatic endoderm cells cultured with Activin A or Activin C as compared to expression of glucagon the pancreatic endocrine cells generated from pancreatic endoderm cells non-treated with Activin A or Activin C.

6. The method of claim 1, wherein expression of ghrelin is suppressed in the pancreatic endocrine cells generated from the pancreatic endoderm cells cultured with Activin A or Activin C as compared to expression of ghrelin in the pancreatic endocrine cells generated from pancreatic endoderm cells non-treated with Activin A or Activin C.

7. The method of claim 1, wherein the pancreatic endoderm cells do not substantially express CDX2 or SOX2.

8. The method of claim 7, wherein the pancreatic endoderm cells cultured with Activin A or Activin C are obtained by a stepwise differentiation of pluripotent cells.

9. The method of claim 8, wherein the pluripotent cells are derived from human embryonic pluripotent cells.

10. The method of claim 1, wherein the pancreatic endoderm cells are human pancreatic endoderm cells.

11. The method of claim 1, wherein the method comprises culturing pancreatic endoderm cells in medium comprising Activin A.

12. The method of claim 1, wherein the method comprises culturing pancreatic endoderm cells in medium comprising Activin C.

13. The method of claim 1, wherein the method further comprises:

differentiating pluripotent stem cells into definitive endoderm cells;

differentiating the definitive endoderm cells into primitive guttube cells;

differentiating the primitive gut tube cells into foregut cells;

differentiating the foregut cells into pancreatic foregut precursor cells; and

differentiating the foregut precursor cells into the pancreatic endoderm cells.